New data demonstrate sustained long-term efficacy of OFEV® on slowing disease progression and safety in patients with IPF
An interim analysis of the INPULSIS®-ON extension trial has confirmed the efficacy and safety of OFEV® (nintedanib) previously observed in the INPULSIS® trials. (September 29, 2015)
New treatment offers hope for an incurable disease
New drug slows lung disease idiopathic pulmonary fibrosis by 50 per cent. – The Hamilton Spectator (ON – August 24, 2015)
Greater hope for a longer life
The approval by Health Canada of a new drug to treat people with idiopathic pulmonary fibrosis (IPF) is a step closer to one day finding a cure. – Brant News (ON – July 20, 2015)
New drug for IPF gives patients hope
It’s just a small capsule, but the power a new drug called OFEV has to create hope for patients living with Idiopathic Pulmonary Fibrosis (IPF) is so much bigger than what would fit in the palm of your hand.
“I thank God for these drugs. That is what gives me hope,” said Jacqui Bowick-Sandor of Smiths Falls who was diagnosed with IPF in 2011. – Inside Ottawa Valley (ON – July 15, 2015)
Health Canada approves OFEV™ (nintedanib) for the treatment of idiopathic pulmonary fibrosis
IPF causes progressive and permanent scarring of the lungs, and over time it becomes difficult to take a deep breath. Dr. Martin Kolb explains.
New treatment option provides hope for Canadians living with fatal lung disease
BURLINGTON, ON July 6, 2015 /CNW/ – Boehringer Ingelheim Ltd. announced today that on June 24, 2015 Health Canada approved OFEV™ (nintedanib) to treat idiopathic pulmonary fibrosis (IPF) in adults. OFEV™ has been clinically proven to reduce the decline in lung function in IPF patients.
IPF is a debilitating and fatal lung disease, which causes progressive, irreversible scarring of the lungs, resulting in lung function decline and difficulty breathing. There is no cure. There are approximately 5,000 to 15,000 Canadians currently living with IPF, and the approval of OFEV™ offers IPF patients a new treatment option to manage this fatal disease.
“The approval of OFEV™ is a significant advancement for IPF patients, offering a proven treatment option to people living with this disease,” says Dr.Martin Kolb, M.D. PhD, Director, Division of Respirology at McMaster University. “Not only does OFEV™ offer another treatment choice for IPF patients to manage their disease, it has been shown to significantly reduce the risk of adjudicated acute exacerbations, which can be deadly.”
The symptoms of IPF – shortness of breath, dry hacking cough, “crackling” sounds in the lungs, and cyanosis (blue lips) – can have a significant impact on quality of life, and make it difficult to perform everyday activities. The median survival rate for people with IPF is two to three years after diagnosis; however, early and accurate diagnosis can help to ensure access to appropriate care.
“The Canadian Pulmonary Fibrosis Foundation welcomes the approval of OFEV™ as a new treatment option for IPF. Every advancement in treatment brings us one step closer to finding a cure, and putting an end to early death from IPF,” says Robert Davidson, President, Canadian Pulmonary Fibrosis Foundation (CPFF). “We must now support efforts to ensure that Canadians have full and timely access to this treatment in a disease area with few choices.”
There is new hope for IPF patients with the Health Canada approval of OFEV™ (nintedanib) for IPF.
OFEV™ was approved on June 24, 2015 and we’ll have more information about availability soon.
With the approval of OFEV™, patients who are diagnosed with IPF now have a choice of therapy. Working with their doctor, patients with IPF can determine which treatment option is right for them.
The Canadian Pulmonary Fibrosis Foundation will be working to ensure affordable access to this treatment in all the provinces.
If you have any questions about this treatment and its availability please contact the Boehringer Ingelheim Customer Care Team at 1-800-263-2425.
Features Robert Davidson and local Stratford resident and IPF patient advocate Garth Matthews. The article effectively outlines Garth’s daily struggle of living with IPF. – The Guardian (PEI – Dec. 18, 2014)
CPFF President Robert Davidson and local IPF patient Garth Matthews are featured and interviewed right after their meeting with Minister of Health Doug Currie. – CBC Compass (PEI – Dec. 18, 2014)
Features Calgary resident and IPF patient advocate, Dick Martin and his physician, Dr. Charlene Fell. Dick is interviewed as he is taking his second dose of Esbriet treatment in Dr. Fell’s office. – CTV News Calgary (AB – Dec. 11, 2014)
Report highlights the funding announcement made in November regarding Alberta’s coverage of Esbriet under the Short Term Exceptional Drug Therapy (STEDT) program. IPF Patient Advocate Dick Martin is quoted that this news is a great relief. – 660 News CFFR-AM (AB – Dec. 2, 2014)
Featuring IPF patient advocate, Harold Tendler. When Harold first started taking Esbriet a year ago, he was paying $2,900 for a four week course of the treatment. However, due to the update in Saskatchewan’s Drug Plan as of November 1st, Esbriet is being covered and Harold paid a fraction of the cost at $492 for his latest course of treatment. – The Assiniboia Times (SK – Nov. 28, 2014)
Featuring IPF patient advocate, Barbara Barr and CPFF president and founder, Robert Davidson, the article highlights many of the recent announcements for the IPF community. Summarizing the journey Ontario IPF patients have endured from the Health Canada approval in 2012 to the negative CDR recommendation, the article also highlights the rentless advocating for public funding by IPF patients, caregivers, physicans and other healthcare professionals that led to Ontario government leading, and other provinces following, to provide access to Esbriet. – King Weekly Sentinel (ON – Nov. 27, 2014)
LUNG HEALTH MONTH — NOVEMBER 2014 We recently participated in Mediaplanet Canada’s Lung Health campaign where we raised awareness about the many struggles of living with IPF, for both patients and caregivers. The piece highlights the CPFF’s “Take a Breather” Caregiver Recognition program, which honours caregivers for their dedication and strength. Patient advocate Barbara Barr was featured, sharing her story and connection to IPF,along with her husband Malcolm Haylock, a 2014 “Take a Breather” recipient,. The campaign was distributed through the Toronto Star’s home and business newspapers on November 13th 2014 and is published online. For the full campaign:
Oakville’s Rob’s Ride nets more than $20K for Canadian Pulmonary Fibrosis Foundation. – Oakville Beaver (ON – Nov. 7, 2014)
New Brunswick resident and IPF patient advocate, Doug Greene describes the struggles of living with IPF like having to carry an oxygen with him at all times and the fact that he is not suitable for a lung transplant at his age. Esbriet is noted as the only available treatment, as it effectively slows the scarring of the lungs, is now available on the New Brunswick Prescription Drug Plan. – Telegraph-Journal (NB – Nov. 3, 2014)
Important series on orphan drugs – part 2 of the series features IPF patient advocate Harold Tendler on Global Regina (SK – Oct. 30, 2014)
Fighting the good fight: Daughter works tirelessly to get treatment for ailing mother – National Post (ON – Oct. 27, 2014)
Promising treatment gives hope to lung disease sufferer – National Post (NB – Oct. 20, 2014)
AVR 97.7 (NB – Oct. 16, 2014)
Patient fights lung disease — and government red tape – National Post (ON – Oct. 14, 2014)
Breathing a sign of relief – National Post (ON – Sept. 30, 2014)
Dr. Charles Chan, an IPF researcher and respirologist, believes the outlook for IPF patients is improving and shares insights on how to better managing this challenging disease.
The video, along with an introduction by Dr. Marla Shapiro in her segment Living With and Managing Idiopathic Pulmonary Fibrosis, aired on September 27th (Toronto) on CTV’s Canadian Health & Family.
Rose McGowan provides a breath of awareness for fatal lung disease – Metro News (Sept. 23, 2014)
Week-long fundraiser shows power of a smile – insideottawavalley.com (Sept. 22, 2014)
Breakfast Television (BT) on City TV Toronto (Sept. 19, 2014) – Rose McGowan media launch for #kissIPFgoodbye campaign
The Social CTV Toronto (Sept. 18, 2014) – Rose McGowan media launch for #kissIPFgoodbye campaign
KiSS 92.5 FM (Sept. 18, 2014) – Rose McGowan media launch for #kissIPFgoodbye campaign
Morning Show Global Toronto (Sept. 18, 2014) – Rose McGowan media launch for #kissIPFgoodbye campaign
Canada AM CTV Toronto (Sept. 18, 2014) – Rose McGowan media launch for #kissIPFgoodbye campaign
Rose McGowan aims to end idiopathic pulmonary fibrosis – Toronto Star (Sept. 18, 2014)
Health Report – 680 News CFTR-AM (ON – Sept. 12, 2014)
Toronto General helping patients cope with rare IPF lung disease – City Centre Mirror (Sept. 18, 2014)
Province to help pay for costly drugs – Brantford Expositor (ON – Sept. 16, 2014)
Hoping for breathing room; Corner Brook woman with rare lung disease lobbying for drug funding – The Western Star (NL – Sept. 8, 2014)
Bowmanville Woman Fights For Drug To Save Her Life – Channel 12 CHEX TV (ON – Sept. 3, 2014)